A novel prochlorperazine nasal spray formulation was introduced as a potential new treatment for migraine headache at the 2014 annual meeting of the American Association of Pharmaceutical Scientists (AAPS). The advance was described by researchers as a first-in-class formulation of the widely used antinausea medication that works as a dopamine receptor antagonist.
Clinical studies have shown that prochlorperazine provides better pain relief than other antimigraine drugs such as sumatriptan, metoclopramide, and ketorolac. But it is only available in tablet form, which has delayed onset of action. The newly developed nasal spray version is faster acting, and is free from preservative-related adverse effects such as mucosal irritation which are typical with vehicles using preservatives such as benzalkonium chloride and potassium sorbate. Despite an absence of preservatives, the new formulation was demonstrated to be stable for up to 120 days.
View related content here.
Read a news story about the development here.
Posted on December 3, 2014